Notably, currently available therapies for RA, such as cytokine (TNF and IL-6) blockers or inhibitors of the JAK-STAT pathway43, exclusively tackle the inflammatory phase of the disease but do not interfere with the underlying processes that initiate the onset of arthritis and therefore often need to be given life-long44. Here, IL6 is linked to arthritic joint disease.